| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8649527 | Cardiovascular Revascularization Medicine | 2017 | 17 Pages |
Abstract
Among patients with Type 1 CMVD, our pilot data suggest favorable changes in IMR, anginal symptoms and activity status with ranolazine treatment. These findings support further evaluation of the effects of ranolazine on microcirculatory function and angina symptoms in a larger cohort of patients with Type 1 CMVD.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Molecular Medicine
Authors
Bina Ahmed, Judith Mondragon, Mark Sheldon, Stacey Clegg,